Measles Outbreak in Bangladesh: Root Cause Analysis Report

Fuente: Zenodo
Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Dr. Qudrat-E-Khuda
Format: Recurso digital
Sprache:Englisch
Veröffentlicht: Zenodo 2026
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1866902132132675584
author Dr. Qudrat-E-Khuda
author_facet Dr. Qudrat-E-Khuda
contents <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">Bangladesh experienced a catastrophic measles outbreak beginning in March 2026, reversing two decades of progress in its Expanded Programme on Immunization (EPI). As of 16 May 2026, official surveillance recorded 64,096 cases — 56,572 suspected and 7,524 confirmed — and 453 deaths, of whom 82% were children under five. Applying the Simons et al. (Lancet, 2012) under-reporting correction model, true case estimates range from 155,000 to 490,000 and actual deaths from 1,400 to 4,000, reflecting severe surveillance failure at the district and upazila level.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">This root cause analysis identifies a cascade of policy, administrative, and institutional failures as the primary drivers. Bangladesh's Health, Population and Nutrition Sector Programme (HPNSP), the legal and operational backbone of EPI since 1998, was effectively cancelled by the Yunus interim government in March 2025 without an adequate replacement framework. Concurrently, the established UNICEF-based Direct Procurement Method was abandoned in favour of a split procurement policy — 50% through UNICEF and 50% through open tender — a decision that bypassed WHO prequalification standards and introduced months of bureaucratic delay. Despite formal warnings from UNICEF as early as December 2025, no corrective action was taken. By March 2026, stocks of six vaccine types, including measles-rubella, were fully exhausted — the first national vaccine stockout in the country's history. Vaccination coverage had collapsed from 97% (MR1, 2023) to approximately 59% in 2025.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">The outbreak response under the successor BNP government was equally deficient: IHR notification to WHO was delayed by three weeks, no national treatment protocol was issued, hospitals lacked triage systems, and the emergency vaccination campaign was stalled by syringe shortages. WHO classified national risk as "high" and warned of cross-border transmission to Myanmar and India.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">The analysis concludes with recommendations for immediate procurement restoration through UNICEF/GAVI, formulation of the Sixth HPNSP, establishment of an autonomous National Immunization Board, and a real-time district-level surveillance system to prevent recurrence.</p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_20245089
institution Zenodo
language eng
publishDate 2026
publisher Zenodo
record_format zenodo
spellingShingle Measles Outbreak in Bangladesh: Root Cause Analysis Report
Dr. Qudrat-E-Khuda
<p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">Bangladesh experienced a catastrophic measles outbreak beginning in March 2026, reversing two decades of progress in its Expanded Programme on Immunization (EPI). As of 16 May 2026, official surveillance recorded 64,096 cases — 56,572 suspected and 7,524 confirmed — and 453 deaths, of whom 82% were children under five. Applying the Simons et al. (Lancet, 2012) under-reporting correction model, true case estimates range from 155,000 to 490,000 and actual deaths from 1,400 to 4,000, reflecting severe surveillance failure at the district and upazila level.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">This root cause analysis identifies a cascade of policy, administrative, and institutional failures as the primary drivers. Bangladesh's Health, Population and Nutrition Sector Programme (HPNSP), the legal and operational backbone of EPI since 1998, was effectively cancelled by the Yunus interim government in March 2025 without an adequate replacement framework. Concurrently, the established UNICEF-based Direct Procurement Method was abandoned in favour of a split procurement policy — 50% through UNICEF and 50% through open tender — a decision that bypassed WHO prequalification standards and introduced months of bureaucratic delay. Despite formal warnings from UNICEF as early as December 2025, no corrective action was taken. By March 2026, stocks of six vaccine types, including measles-rubella, were fully exhausted — the first national vaccine stockout in the country's history. Vaccination coverage had collapsed from 97% (MR1, 2023) to approximately 59% in 2025.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">The outbreak response under the successor BNP government was equally deficient: IHR notification to WHO was delayed by three weeks, no national treatment protocol was issued, hospitals lacked triage systems, and the emergency vaccination campaign was stalled by syringe shortages. WHO classified national risk as "high" and warned of cross-border transmission to Myanmar and India.</p> <p class="font-claude-response-body break-words whitespace-normal leading-[1.7]">The analysis concludes with recommendations for immediate procurement restoration through UNICEF/GAVI, formulation of the Sixth HPNSP, establishment of an autonomous National Immunization Board, and a real-time district-level surveillance system to prevent recurrence.</p>
title Measles Outbreak in Bangladesh: Root Cause Analysis Report
url https://doi.org/10.5281/zenodo.20245089